DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

For ocular rosacea, dermatologists can do more than hand off patients to ophthalmology by asking the right questions and ...

SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027Together with SOL-1, these ...

Public interest has recently turned to the human eye and the Pfizer COVID-19 Vaccine. Two peer-reviewed papers have helped ...

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved tar ...

Ocular Therapeutix (OCUL) remains in the red, with losses expanding at an average rate of 22.7% per year over the past five years. While the company is expected to remain unprofitable for at least the ...

Research and development expenses for the third quarter of 2025 were $52.4 million versus $37.1 million for the comparable quarter in 2024, reflecting an increase in overall clinical expenses ...

Advancing wet AMD & diabetic eye trials, strong cash runway to 2028, and aiming for a market-leading superiority label.

The SOL-R registrational trial (NCT06495918) of OTX-TKI (AXPAXLI) by Ocular Therapeutix has reached its randomization target of 555 patients.

This prospective study aimed to clinically correlate the various ocular findings with the neurological status in cases of closed head injury. A total of 200 consecutive cases of closed head injury ...

Ocular Therapeutix (OCUL) granted inducement awards to one newly hired non-executive employee. The award was made as an inducement material to the ...